- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00840255
Brief Behavioral Treatment of Insomnia in Military Veterans: Phase 2 (BBTIMVII) (BBTIMVII)
15 de junio de 2012 actualizado por: Anne Germain, University of Pittsburgh
Treatment of Insomnia in Military Veterans:Phase 2
The purpose of this study is to adapt and test the effects of a 4-week behavioral treatment that targets chronic insomnia (lasting >1 month) in service members returning from Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF), finalizing a treatment manual.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Descripción detallada
Insomnia is one of the most common reasons for referral to mental health services in active duty personnel.
Chronic insomnia often persists post-deployment, contributes to poor mental and physical health outcomes, and requires targeted interventions.
Effective behavioral treatments of insomnia have not been adapted and tested for the treatment of chronic insomnia comorbid to combat-related mental disorders and stress reactions.
In addition, effective behavioral insomnia treatments are typically delivered over an 8-week period.
This format may not be easily exportable to primary and community care settings where military returnees and veterans seek help.
The goal is to adapt and test the effects of a 4-week behavioral treatment that targets chronic insomnia (lasting >1 month) in service members returning from Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF), and who present with the typical psychiatric comorbidities associated of combat-related anxiety and mood disorders and stress reactions.
We call this intervention the Brief Behavioral Treatment of Insomnia for Military Veterans (BBTI-MV).
The proposed study includes two phases.
The specific aims of Phase II are: (1) To explore the effects of BBTI-MV on sleep and daytime symptoms of psychiatric distress.
We anticipate that participants randomized to BBTI-MV will show a higher categorical response rate and remission for sleep symptoms than subjects randomized to IC. (2) To evaluate in a preliminary manner the durability of therapeutic gains and by conducting a naturalistic follow-up assessment six months post-treatment in responders.
(3) To explore whether the nature of combat-related experiences, time since deployment and since, return to the US, deployment theater, medication use and change in dosage, mood and anxiety or disorders affect sleep treatment adherence and outcomes.
Tipo de estudio
Intervencionista
Inscripción (Actual)
40
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15237
- Western Psychiatric Institute & Clinic
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- Age is 18 years old and older
- Military returnees from OIF/OEF
Meet diagnostic criteria for chronic insomnia as defined by:
a. Complaint of sleep latency >30 minutes, or wake time after sleep onset >30 minutes, or Sleep Efficiency <85%, or a complaint of non-restorative sleep
- Frequency of insomnia complaint >3 times per week;
- Duration of insomnia complaint >1 month
- Associated with at least one daytime consequences
- If using sleep medications, medication and dosage have not been changed in the past month, and will remain unchanged for the duration of the acute treatment phase of the study (i.e., 4 weeks)
- If using other psychotropic medications, medication and dosage have not been changed in the past 2 months, and will remain unchanged for the duration of the acute treatment phase of the study (i.e., 4 weeks)
Exclusion Criteria:
- Active duty personnel, or reservists/national guards scheduled to re-deploy if their departure date is < 2 months from the consent date
- Untreated, current, and severe PTSD as determined on the SCID.
- Untreated, current, and severe Major Depressive Disorder as determined by the Structured Clinical Interview for DSM-IV and a score > 30 on the Beck Depression Inventory
- Psychotic or bipolar disorder
- Current substance or alcohol use disorder as determined by the SCID or by positive drug toxicology results
- Unstable medical condition
- Hospitalization in the previous 2 weeks for a medical condition or surgery for which recovery overlaps with the study onset and duration
- Seizure disorder or open skull brain injury.
- Current sleep disorders such as nightmare disorder, restless legs syndrome, or suspected sleep disorder requiring polysomnographic assessment, such as obstructive sleep apnea or periodic leg movements.
- Sleep apnea revealed during the screening sleep study.
- Pregnancy.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador activo: Breif Behavioral Treatment of Insomnia
Effective behavioral insomnia treatments are typically delivered over an 8-week period.
This format may not be easily exportable to primary and community care settings where military returnees and veterans seek help.
The goal here is to test the effects of a 4-week behavioral treatment that targets chronic insomnia (lasting >1 month) in service members returning from Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF), and who present with the typical psychiatric comorbidities associated of combat-related anxiety and mood disorders and stress reactions.
|
Twenty participants will be randomized to BBTI-MV.
As previously described, the intervention will be delivered over 4 consecutive weeks, which include individual face-to-face visits on Weeks 1 and 3, and telephone appointments on Weeks 2 and 4. Interventions will be delivered at Western Psychiatric Institutes and Clinic.
If possible, (according to space availability), the face-to-face sessions may also be conducted at the VAPHS clinics or at Reserve and Veterans Centers locally and regionally to strengthen our relations with local care and services providers and centers, and to facilitate future collaborative efforts.
The duration of the first treatment visit is 45-minutes, and the follow-up visit on Week 3 will last no more than 30 minutes.
Brief (<20 minutes) telephone sessions will be conducted on Weeks 2 and 4.
|
Otro: Information Control
This arm of the study does not receive the Brief Behavioral Treatment for Insomnia.
This arm will act as the control arm.
|
Participants will receive two brochures from the American Academy on Sleep Medicine of Sleep Hygiene and on Insomnia.
The therapists will read the content of the 2 brochures with participants, and discuss how the information provide relates to individual participants' sleep experiences.
No recommendations for altering sleep schedules will be made by the assigned therapist.
Participants will be instructed to read these two brochures over the course of the following week, and to consider how the information provided in the brochures related to their own sleep patterns
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
Pittsburgh Sleep Quality Index (PSQI)
Periodo de tiempo: Baseline and Post Intervention
|
Baseline and Post Intervention
|
Pittsburgh Sleep Diary
Periodo de tiempo: Weekly
|
Weekly
|
PSQI Addendum for PTSD (PSQIA)
Periodo de tiempo: Baseline and Post
|
Baseline and Post
|
Sleep Quality defined by: PIRS-20 and ISI
Periodo de tiempo: Screening,Baseline, and Post
|
Screening,Baseline, and Post
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
PTSD symptom severity as measured by the CAPS
Periodo de tiempo: Screening
|
Screening
|
Post Sleep Self Report: PSEQ-SV and POST
Periodo de tiempo: Screening
|
Screening
|
Depression: BDI
Periodo de tiempo: Baseline and Post
|
Baseline and Post
|
Anxiety: BAI
Periodo de tiempo: Baseline and Post
|
Baseline and Post
|
Medical History: MHQ, MEDHIST_2WK, MOS
Periodo de tiempo: Screening, Baseline, and Post
|
Screening, Baseline, and Post
|
Trauma History: THQ,CES,PCL-C,ICG
Periodo de tiempo: Screening, Baseline, and Post
|
Screening, Baseline, and Post
|
Sleepiness: EPWORTH, BASS
Periodo de tiempo: Screening, Baseline, and Post
|
Screening, Baseline, and Post
|
Mood and Behavior: BIS/BAS, SMITH, PANAS
Periodo de tiempo: Screening, Baseline, and Post
|
Screening, Baseline, and Post
|
Expectations and Satisfaction: TEQ-94, Client Satisfaction Survey
Periodo de tiempo: Baseline and Post
|
Baseline and Post
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Anne Germain, PhD, University of Pittsburgh, Department of Psychiatry
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Enlaces Útiles
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de abril de 2009
Finalización primaria (Actual)
1 de abril de 2012
Finalización del estudio (Actual)
1 de abril de 2012
Fechas de registro del estudio
Enviado por primera vez
9 de febrero de 2009
Primero enviado que cumplió con los criterios de control de calidad
9 de febrero de 2009
Publicado por primera vez (Estimar)
10 de febrero de 2009
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
18 de junio de 2012
Última actualización enviada que cumplió con los criterios de control de calidad
15 de junio de 2012
Última verificación
1 de junio de 2012
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- PRO08070327
- NIMH: 1 R34 MH080696
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre BBTI-MV
-
Royal Marsden NHS Foundation TrustImperial College London; Institute of Cancer Research, United Kingdom; RM Partners...ReclutamientoDe fumar | Alcoholismo | Enfermedades urológicas | Hipertensión | Diabetes | Cancer de prostata | Cáncer de vejiga | Cáncer renal | Cáncer urológico | Problema de salud mental | Cáncer de testículoReino Unido
-
Daping Hospital and the Research Institute of Surgery...Desconocido
-
Taipei Medical UniversityReclutamientoInsomnio | Lesión cerebral traumáticaTaiwán
-
Rutgers, The State University of New JerseyReclutamientoDepresión | Desorden del espectro autista | Autismo | Trastorno del espectro autista con alteración del lenguaje funcionalEstados Unidos
-
National Cheng-Kung University HospitalReclutamientoAdultos mayores | Insomnio crónico | Higiene del sueñoTaiwán
-
Johns Hopkins UniversityReclutamientoInsomnio | Trastornos por uso de sustanciasEstados Unidos
-
Brigham and Women's HospitalHarvard Medical School (HMS and HSDM)TerminadoCalidad de vida | Dolor | Insomnio | DormirEstados Unidos
-
Bandim Health ProjectAarhus University Hospital; Rigshospitalet, DenmarkTerminadoMortalidad | Hospitalización | Eventos adversosGuinea-Bisáu
-
Themis Bioscience GmbHWalter Reed Army Institute of Research (WRAIR)TerminadoChikungunyaPuerto Rico
-
Fuda Cancer Hospital, GuangzhouTerminadoNeoplasias PulmonaresPorcelana